Dr. Jennifer Foster, MD
Claim this profileBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Expert in Neuroblastoma
Expert in Cancer
34 reported clinical trials
53 drugs studied
Area of expertise
1Neuroblastoma
Global LeaderStage IV
MYC positive
Stage I
2Cancer
Global LeaderStage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Jennifer Foster, MD is currently running
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting1 award Phase 1 & 213 criteria
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
More about Jennifer Foster, MD
Clinical Trial Related3 years of experience running clinical trials · Led 34 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Jennifer Foster, MD has experience with
- Cyclophosphamide
- Cytology Specimen Collection Procedure
- Laboratory Biomarker Analysis
- Larotrectinib
- Palbociclib
- Erdafitinib
Breakdown of trials Jennifer Foster, MD has run
Neuroblastoma
Cancer
Solid Tumors
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer Foster, MD specialize in?
Jennifer Foster, MD focuses on Neuroblastoma and Cancer. In particular, much of their work with Neuroblastoma has involved Stage IV patients, or patients who are MYC positive.
Is Jennifer Foster, MD currently recruiting for clinical trials?
Yes, Jennifer Foster, MD is currently recruiting for 8 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Jennifer Foster, MD has studied deeply?
Yes, Jennifer Foster, MD has studied treatments such as Cyclophosphamide, Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis.
What is the best way to schedule an appointment with Jennifer Foster, MD?
Apply for one of the trials that Jennifer Foster, MD is conducting.
What is the office address of Jennifer Foster, MD?
The office of Jennifer Foster, MD is located at: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.